Nippon Life Global Investors Americas’s Alexion Pharmaceuticals ALXN Stock Holding History

Nippon Life Global Investors Americas’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-36,230	Closed	-$4.15M	–	162
2020 Q3	$4.15M	Hold	36,230	–	–	0.27%	85
2020 Q2	$4.07M	Sell	36,230 -20,730	-36%	-$2.2M	0.29%	84
2020 Q1	$5.12M	Buy	56,960 +33,660	+144%	+$3.3M	0.45%	62
2019 Q4	$2.52M	Hold	23,300	–	–	0.17%	115
2019 Q3	$2.28M	Hold	23,300	–	–	0.17%	115
2019 Q2	$3.05M	Buy	+23,300	New	+$3M	0.23%	101
2015 Q2	–	Sell	-17,300	Closed	-$3M	–	131
2015 Q1	$3M	Buy	17,300 +1,920	+12%	+$348K	0.27%	108
2014 Q4	$2.85M	Hold	15,380	–	–	0.26%	111
2014 Q3	$2.55M	Buy	15,380 +4,520	+42%	+$742K	0.24%	117
2014 Q2	$1.7M	Hold	10,860	–	–	0.16%	126
2014 Q1	$1.65M	Buy	+10,860	New	+$1.73M	0.16%	132
2013 Q3	–	Sell	-38,890	Closed	-$3.59M	–	145
2013 Q2	$3.59M	Buy	+38,890	New	+$3.75M	0.4%	105

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nippon Life Global Investors Americas's ALXN Position: Q4 2020 in Review

Nippon Life Global Investors Americas sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 36,230 shares — an estimated $4.15M sold.

Nippon Life Global Investors Americas first reported a position in ALXN in Q2 2013 and held it in 12 quarters. The position peaked at $5.12M in Q1 2020. 825 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Nippon Life Global Investors Americas reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Nippon Life Global Investors Americas sold 36,230 Alexion Pharmaceuticals shares in Q4 2020, an estimated $4.15M.
Nippon Life Global Investors Americas first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Nippon Life Global Investors Americas's Alexion Pharmaceuticals position peaked at $5.12M in Q1 2020.
825 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Nippon Life Global Investors Americas's 13F filing for Q4 2020, filed 1 Feb 2021.